Fig. 2: BPX-601 cell expansion and persistence and cytokine profiles in peripheral blood in response to rimiducid.

CAR T cell expansion and persistence in peripheral blood of a mPDAC (n = 11) and b mCRPC (n = 9) patients enrolled in cohorts 5B (orange) and 5C (purple) measured by qPCR-based detection vector copy number (VCN) in genomic DNA. BPX-601 pharmacokinetics over the 1st month for all subjects and beyond that time for evaluable patients are shown. LLOQ lower limit of quantitation. Effect of rimiducid on CAR T cell and cytokine production in patients with c mPDAC (n = 11) or d mCRPC (n = 9, except n = 8 for rimiducid PK) enrolled in cohorts 5B and 5C after first rimiducid dose. Rimiducid PK (black), VCN (red), and IFN-γ concentration (orange) in peripheral blood (mean ± SD) are shown to illustrate the effect of rimiducid dosing on VCN and IFN-γ production (as an example of multiple cytokines’/chemokines’ response to rimiducid infusion). Main figure shows data during the first 14 days of treatment, and inserts highlight data during the day after rimiducid dosing, with timeline (days) adjusted to align BP-601 and rimiducid infusions across all patients. Cytokine and chemokine response during 1st month in patients with e mPDAC (n = 11) or f mCRPC (n = 9) enrolled in cohorts 5B and 5C. Median maximum fold change from pretreatment for each cytokine/chemokine is shown for the first 4 weeks of treatment, plotted as pre-dose and peak observed after each infusion (BPX-601 or rimiducid, as indicated). Baseline and peak cytokines of patients from cohorts 5B and 5C are shown for BPX-601 and first rimiducid dose, then only patients from cohort 5C are shown for rimiducid doses 2 and 3. Source data are provided as a Source Data file.